bafetinib

(redirected from NS-187)

bafetinib

A Bcr-Abl/Lyn dual tyrosine kinase inhibitor, which may suppress the growth of CLL cells by inhibition of Lyn kinase. Imatinib-resistant CLL cells are associated with an overexpression of Lyn kinase, a factor in the proliferation and survival of B-CLL cells. It has no effect on c-Src kinase activity, and may be less toxic than other broad Src family kinase inhibitors. Bafetinib has shown therapeutic potential in phase-II trials in patients with relapsed or refractory B-cell chronic lymphocytic leukaemia.
References in periodicals archive ?
Under the agreement terms, INNOVIVE Pharmaceuticals will be licensed to exclusively develop and market NS-187, a drug candidate developed by Nippon Shinyaku, worldwide except in Japan.
NS-187, which is a molecular targeted agent in the preclinical stage, is intended for the treatment of chronic myelogenous leukemia (CML).
a biopharmaceutical company headquartered in Manhattan, announced today that it has licensed worldwide development rights for NS-187 in all countries except Japan, from Nippon Shinyaku Co.
NS-187 is an orally bioavailable, rationally designed, dual Bcr-Abl and Lyn kinase inhibitor.
In addition to its Bcr-Abl inhibitory properties, NS-187 was designed to inhibit Lyn kinase.
I am very excited about NS-187 because of its potent inhibition of Bcr-Abl and its specificity for Lyn which could contribute to a unique efficacy and toxicity profile," said Hagop M.
We are pleased to add NS-187 to INNOVIVE's oncology pipeline.